Cerebral metabolic changes during treatment of subacute cerebral infarction by alpha and beta adrenergic blockade with phenoxybenzamine and propranolol.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002245:Carbon Dioxide / Q000097:blood; D002496:Central Venous Pressure / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000378:metabolism; D004569:Electroencephalography; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D005971:Glutamates / Q000378:metabolism; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010085:Oxidative Phosphorylation / Q000187:drug effects; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects*; D010313:Partial Pressure; D010643:Phenoxybenzamine / Q000494:pharmacology / Q000627:therapeutic use*; D010710:Phosphates / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D014280:Triglycerides / Q000378:metabolism; D014475:Uncoupling Agents / Q000494:pharmacology; D014690:Venous Pressure / Q000187:drug effects
D005230:Fatty Acids, Nonesterified; D005971:Glutamates; D010710:Phosphates; D014280:Triglycerides; D014475:Uncoupling Agents; D010643:Phenoxybenzamine; D002245:Carbon Dioxide; D011433:Propranolol; D005947:Glucose; D010100:Oxygen